The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study

• Published in: Osteoporosis international Vol. 17; no. 9; pp. 1410 - 1419
• Main Authors: Richards, J. B., Joseph, L., Schwartzman, K., Kreiger, N., Tenenhouse, A., Goltzman, D.
• Format: Journal Article
• Language: English
• Published: London Springer 01.09.2006; Springer Nature B.V
• Subjects: Acetaminophen - pharmacology; Adult; Aged; Biological and medical sciences; Body Mass Index; Bone density; Bone Density - drug effects; Bones, joints and connective tissue. Antiinflammatory agents; Clinical outcomes; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - pharmacology; Cyclooxygenase 2 Inhibitors - therapeutic use; Diseases of the osteoarticular system; Dose-Response Relationship, Drug; Drug therapy; Estrogen Replacement Therapy; Female; Femur - physiology; Hip Joint - physiology; Humans; Investigative techniques, diagnostic techniques (general aspects); Lumbar Vertebrae - physiology; Male; Medical sciences; Middle Aged; Older people; Osteoarthritis - drug therapy; Osteoarticular system. Muscles; Osteoporosis; Osteoporosis - chemically induced; Osteoporosis - physiopathology; Osteoporosis. Osteomalacia. Paget disease; Pharmacology. Drug treatments; Prospective Studies; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Sex Factors; Canada; Non steroidal antiinflammatory agent; Osteoporosis; Diseases of the osteoarticular system; Rheumatology; Bone mineral density; Inflammation; Cyclooxygenase 2 inhibitor; Cyclooxygenase-2 inhibitors

The use of cyclooxygenase-2 (COX-2) inhibitors has been demonstrated to not only impair load-induced bone formation but also prevent menopause-associated bone loss. We hypothesized that COX-2 inhibitor use would be associated with increased bone mineral density (BMD) in postmenopausal women not usin...